PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies

被引：0

作者：

Diab, A. ^{[1
]}

Hurwitz, M. E. ^{[2
]}

Tannir, N. ^{[3
]}

Bernatchez, C. ^{[1
]}

Haymaker, C. ^{[1
]}

Bentebibel, S. E. ^{[1
]}

Curti, B. D. ^{[4
,5
]}

Wong, M. K. K. ^{[1
]}

Gergel, I. ^{[6
]}

Tagliaferri, M. ^{[7
]}

Zalevsky, J. ^{[8
]}

Hoch, U. ^{[9
]}

Aung, S. ^{[7
]}

Imperiale, M. ^{[7
]}

Cho, D. ^{[10
]}

Tykodi, S. S. ^{[11
,12
]}

Puzanov, I. ^{[13
]}

Kluger, H. ^{[14
]}

Hwu, P. ^{[1
]}

Sznol, M. ^{[15
]}

机构：

[1] MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX USA

[2] Yale Sch Med, Div Med Oncol, Dept Internal Med, New Haven, CT USA

[3] MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX USA

[4] Providence Canc Ctr, Dept Genitourinary Oncol Res, Portland, OR USA

[5] Earle A Chiles Res Inst, Portland, OR USA

[6] Nektar Therapeut, Dept Drug Dev, San Francisco, CA USA

[7] Nektar Therapeut, Dept Clin Dev, San Francisco, CA USA

[8] Nektar Therapeut, Dept Biol & Preclin Dev, San Francisco, CA USA

[9] Nektar Therapeut, Dept Clin Pharmacol, San Francisco, CA USA

[10] NYU Med Oncol Associates, Dept Med Oncol, New York, NY USA

[11] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[12] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[13] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA

[14] Yale Breast Ctr, Dept Med Oncol, New Haven, CT USA

[15] Yale Univ, Sch Med Med Oncol, Dept Med Oncol, New Haven, CT USA

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1212TiP

引用

页数：1

共 50 条

[41] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States [J].

Andrea Wang-Gillam ;

William Schelman ;

Stacey Ukrainskyj ;

Caly Chien ;

Martha Gonzalez ;

Zhao Yang ;

Marek Kania ;

Heather Yeckes-Rodin .

Investigational New Drugs, 2023, 41 (6) :851-860

[42] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States [J].

Wang-Gillam, Andrea ;

Schelman, William ;

Ukrainskyj, Stacey ;

Chien, Caly ;

Gonzalez, Martha ;

Yang, Zhao ;

Kania, Marek ;

Yeckes-Rodin, Heather .

INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) :851-860

[43] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations. [J].

Heymach, John ;

Opdam, Frans ;

Barve, Minal A. ;

Gibson, Neil ;

Sadrolhefazi, Behbood ;

Serra, Josep ;

Yamamoto, Noboru .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[44] Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study [J].

Kudo, Toshihiro ;

Murai, Yoshiyuki ;

Kojima, Yoshitsugu ;

Uehara, Kenji ;

Satoh, Taroh .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) :354-362

[45] A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations. [J].

Heymach, John ;

Opdam, Frans ;

Barve, Minal ;

Gibson, Neil ;

Sadrolhefazi, Behbood ;

Serra, Josep ;

Yamamoto, Noboru .

CANCER RESEARCH, 2022, 82 (12)

[46] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies. [J].

Fathi, Amir Tahmasb ;

Donnellan, William Bruce ;

Lyons, Roger M. ;

Maris, Michael B. ;

Kim, Tae Min ;

Kim, Won Seog ;

Schiller, Gary J. ;

Abboud, Camille N. ;

Arellano, Martha Lucia ;

Cull, Elizabeth H. ;

Yee, Karen W. L. ;

Townsley, Danielle Michelle ;

Wang, Fujun ;

Bothos, John G. ;

Yao, Nai-Shun ;

Salles, Gilles A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[47] Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study [J].

Hamadani, Mehdi ;

Collins, Graham P. ;

Caimi, Paolo F. ;

Samaniego, Felipe ;

Spira, Alexander ;

Davies, Andrew ;

Radford, John ;

Menne, Tobias ;

Karnad, Anand ;

Zain, Jasmine M. ;

Fields, Paul ;

Havenith, Karin ;

Cruz, Hans G. ;

He, Shui ;

Boni, Joseph ;

Feingold, Jay ;

Wuerthner, Jens ;

Horwitz, Steven .

LANCET HAEMATOLOGY, 2021, 8 (06) :E433-E445

[48] A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma [J].

Shah, Nina D. ;

Turtle, Cameron J. ;

Cowan, Andrew J. ;

Chavez, Julio C. ;

Budde, Lihua E. ;

Marcondes, Mario Q. ;

Lee, Zachary ;

Lin, Wei ;

Zalevsky, Jonathan ;

Tagliaferri, Mary ;

Patel, Krina K. .

BLOOD, 2019, 134

[49] A phase I open-label dose-escalation study of AL2846 in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma. [J].

Liu, Rui ;

Deng, Ting ;

Bai, Ming ;

Zhang, Le ;

Ning, Tao ;

Wang, Xia ;

Ji, Zhi ;

Yang, Yuchong ;

Ge, Shaohua ;

Li, Hongli ;

Duan, Jingjing ;

Ba, Yi .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[50] A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors. [J].

Alistar, Angela Tatiana ;

El-Khoueiry, Anthony B. ;

Mahalingam, Devalingam ;

Mita, Monica M. ;

Kang, Hwankyu ;

Yang, Yeong-In ;

Ahn, Jiye ;

Kim, Jeongjun ;

Choi, Baejung ;

Jeon, Yeejin ;

Jung, Chunwon ;

Jeon, Borami ;

Kim, Jaeseung ;

Nam, Kiyean .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →